What is Rapid Micro Biosystems?
Rapid Micro Biosystems is at the forefront of innovation in the life sciences sector, providing essential automation solutions designed to streamline the manufacturing and release processes for a wide array of healthcare products. The company's flagship Growth Direct System is engineered to replace outdated, manual microbial quality control (MQC) testing workflows. By bringing the quality control lab directly to the manufacturing floor, the Growth Direct System offers enhanced accuracy, operational efficiency, and compliance with data integrity regulations, ultimately ensuring a more consistent and reliable supply of vital healthcare products. The company's operations are based in Lowell, Massachusetts, with additional global presence.
How much funding has Rapid Micro Biosystems raised?
Rapid Micro Biosystems has raised a total of $396.7M across 10 funding rounds:
Series B
$32.6M
Private Equity
$6M
Debt
$6M
Series C
$25M
Other Financing Round
$60M
Other Financing Round
$120M
Other Financing Round
$81M
Debt
$45M
Series B (2013): $32.6M supported by Kleiner Perkins Caufield & Byers, Longitude Capital, Quaker Partners, TPG Biotech, and TVM Capital
Private Equity (2014): $6M featuring Kleiner Perkins Caufield & Byers, TVM Capital, Quaker Partners, TPG Biotech, and Longitude Capital
Debt (2015): $6M, investors not publicly disclosed
Series C (2015): $25M with participation from TPG Biotech, Richard K. Mellon and Sons, Quaker Partners, Hepalink, Longitude Capital, Kleiner Perkins Caufield & Byers, and TVM Capital
Other Financing Round (2018): $60M led by Bain Capital and Xeraya Capital
Other Financing Round (2020): $120M supported by Longitude Capital, Endeavour Vision, Asahi Kasei Medical, Xeraya Capital, Bain Capital, and Ally Bridge Group
Other Financing Round (2021): $81M featuring Quaker BioVentures, Ally Bridge Group, Longitude Capital, Endeavour Vision, Bain Capital, BlackRock, Adage Capital Management, Asahi Kasei Corporation, Caas Capital Management, D1 Capital Partners, Sunley House Capital Management, Xeraya Capital, and T. Rowe Price
Debt (2025): $45M backed by Trinity Capital
Key Investors in Rapid Micro Biosystems
Quaker BioVentures
Quaker BioVentures is an East Coast-focused healthcare investment firm that pursues a traditional venture capital and growth equity strategy, leading equity investments in healthcare companies across various stages of development. Their expertise spans biopharmaceuticals, medical technologies, and healthcare services.
Longitude Capital
Longitude Capital is a venture capital firm dedicated to the healthcare sector, investing in biotechnology, medical technology, and health solutions companies. They combine sector expertise with flexible capital and active partnership to help innovators scale and improve patient care.
Endeavour Vision
Endeavour Vision is an investment advisory firm specializing in transformative healthcare technologies, particularly in medical devices and digital health. They support entrepreneurs in developing innovative solutions to address unmet healthcare needs and modernize healthcare systems.
What's next for Rapid Micro Biosystems?
The substantial capital infusion, including the recent major strategic investment, positions Rapid Micro Biosystems for accelerated growth and market expansion. This financing is expected to fuel further development of its automated MQC solutions, enhance its global reach, and support its mission to revolutionize quality control in pharmaceutical manufacturing. The company's focus on critical healthcare products suggests a strategic trajectory aimed at addressing evolving industry demands for speed, accuracy, and compliance in an increasingly complex regulatory environment. This backing will likely enable Rapid Micro Biosystems to solidify its market leadership and continue its impact on the safe and efficient production of life-saving therapies.
See full Rapid Micro Biosystems company page
